Literature DB >> 3691624

Effect of dose size on amodiaquine pharmacokinetics after oral administration.

P A Winstanley1, G Edwards, M L Orme, A M Breckenridge.   

Abstract

Plasma and urine concentrations of amodiaquine (AQ) and desethylamodiaquine (AQm) have been measured after oral administration of AQ 200, 400 and 600 mg in randomised order to 6 healthy subjects. The relationships between AQ dose size and the areas under the plasma concentration vs time curves for AQ and AQm were linear. Likewise there were linear relationships between AQ dose size and the mass of both AQ and AQm excreted in the urine. These data indicate that after oral administration within this dose range AQ displays first-order pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691624     DOI: 10.1007/bf00637573

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents.

Authors:  E G Rhodes; J Ball; I M Franklin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-15

2.  Amodiaquine induced agranulocytosis and liver damage.

Authors:  K A Neftel; W Woodtly; M Schmid; P G Frick; J Fehr
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-15

3.  Isolation, characterization and standardization of a major metabolite of amodiaquine by chromatographic and spectroscopic methods.

Authors:  F C Churchill; D L Mount; L C Patchen; A Björkman
Journal:  J Chromatogr       Date:  1986-04-25

4.  Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria.

Authors:  C S Hatton; T E Peto; C Bunch; G Pasvol; S J Russell; C R Singer; G Edwards; P Winstanley
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

5.  Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics.

Authors:  M Frisk-Holmberg; Y Bergkvist; B Domeij-Nyberg; L Hellström; F Jansson
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

6.  Amodiaquine-induced agranulocytosis: toxic effect of amodiaquine in bone marrow cultures in vitro.

Authors:  D E Lind; J A Levi; P C Vincent
Journal:  Br Med J       Date:  1973-02-24

7.  Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya.

Authors:  W M Watkins; D G Sixsmith; H C Spencer; D A Boriga; D M Kariuki; T Kipingor; D K Koech
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

8.  The disposition of amodiaquine in man after oral administration.

Authors:  P Winstanley; G Edwards; M Orme; A Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

9.  Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans.

Authors:  F C Churchill; L C Patchen; C C Campbell; I K Schwartz; P Nguyen-Dinh; C M Dickinson
Journal:  Life Sci       Date:  1985-01-07       Impact factor: 5.037

  9 in total
  10 in total

1.  Pharmacokinetics of intramuscular amopyroquin in healthy subjects and determination of a therapeutic regimen for Plasmodium falciparum malaria.

Authors:  F Verdier; E Pussard; F Clavier; J Le Bras; C Gaudebout
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  Effect of monodesethyl amodiaquine on human polymorphonuclear neutrophil functions in vitro.

Authors:  M T Labro; J el Benna
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 3.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients.

Authors:  V Sinou; L Tshilolo Muepu Malaika; N Taudon; R Lwango; S Sese Alegre; L Bertaux; F Sugnaux; D Parzy; A Benakis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.441

5.  Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro.

Authors:  M T Labro; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

6.  Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.

Authors:  Joel Tarning; Palang Chotsiri; Vincent Jullien; Marcus J Rijken; Martin Bergstrand; Mireille Cammas; Rose McGready; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White; Francois Nosten; Niklas Lindegardh
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

Review 7.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers.

Authors:  Visweswaran Navaratnam; Surash Ramanathan; Mohd Suhaimi Ab Wahab; Gan Siew Hua; Sharif Mahsufi Mansor; Jean-René Kiechel; Michel Vaillant; Walter R J Taylor; Piero Olliaro
Journal:  Eur J Clin Pharmacol       Date:  2009-04-30       Impact factor: 2.953

9.  Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers.

Authors:  Catherine Orrell; Francesca Little; Peter Smith; Peter Folb; Walter Taylor; Piero Olliaro; Karen I Barnes
Journal:  Eur J Clin Pharmacol       Date:  2008-04-16       Impact factor: 2.953

10.  In Vivo Activity of Repurposed Amodiaquine as a Host-Targeting Therapy for the Treatment of Anthrax.

Authors:  Mikhail Martchenko Shilman; Gloria Bartolo; Saleem Alameh; Johnny W Peterson; William S Lawrence; Jennifer E Peel; Satheesh K Sivasubramani; David W C Beasley; Christopher K Cote; Samandra T Demons; Stephanie A Halasahoris; Lynda L Miller; Christopher P Klimko; Jennifer L Shoe; David P Fetterer; Ryan McComb; Chi-Lee C Ho; Kenneth A Bradley; Stella Hartmann; Luisa W Cheng; Marina Chugunova; Chiu-Yen Kao; Jennifer K Tran; Aram Derbedrossian; Leeor Zilbermintz; Emiene Amali-Adekwu; Anastasia Levitin; Joel West
Journal:  ACS Infect Dis       Date:  2021-07-04       Impact factor: 5.084

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.